

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete If Known

Application Number	10/799,302
Filing Date	03/12/2004
First Named Inventor	JEFFREY S. KIEL
Art Unit	1615
Examiner Name	
Attorney Docket Number	455-030

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Code ² (if known)				
	JS	1	us- 6,306,904	10/23/2001	GORDZIEL	
		2	us- 6,287,597	09/11/2001	GORDZIEL	
		3	us- 6,187,315	02/13/2001	FALCON	
		4	us- 6,117,452	09/12/2000	AHLGREN ET AL.	
		5	us- 6,063,770	05/16/2000	FALCON	
		6	us- 6,037,358	03/14/2000	GORDZIEL	
		7	us- 5,759,579	06/02/1998	SINGH ET AL.	
		8	us- 5,663,415	09/02/1997	CHOPDEKAR ET AL.	
		9	us- 5,614,178	03/25/1997	BLOOM ET AL.	
		10	us- 5,599,846	02/04/1997	CHOPDEKAR ET AL.	
		11	us- 5,164,398	11/17/1992	SIMS ET AL.	
		12	us- 5,025,019	06/18/1991	SUNSHINE ET AL.	
		13	us- 4,839,354	06/13/1989	SUNSHINE ET AL.	
		14	us- 4,767,402	08/30/1988	KOST ET AL.	
		15	us- 4,749,723	06/07/1988	SUNSHINE ET AL.	
		16	us- 4,749,722	06/07/1988	SUNSHINE ET AL.	
		17	us- 4,749,721	06/07/1988	SUNSHINE ET AL.	
		18	us- 4,749,711	06/07/1988	SUNSHINE ET AL.	
		19	us- 4,749,697	06/07/1988	SUNSHINE ET AL.	
JS	20	us- 4,619,934	10/28/1986	SUNSHINE ET AL.		

FOREIGN PATENT DOCUMENTS[illegible]

Examiner Signature	/Jagadishwar Samala/	Date	10/26/2006
		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div>Complete If Known</div> <div>Application Number10/799,302</div> <div>Filing Date03/12/2004</div> <div>First Named InventorJEFFREY S. KIEL</div> <div>Art Unit1615</div> <div>Examiner Name</div> <div>Attorney Docket Number455-030</div>	
<div>INFORMATION DISCLOSURE</div> <div>STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>					
Sheet	2	of	3		

[illegible][illegible]

Examiner Signature	/Jagadishwar Samal	Date (10/26/2006) Considered
-----------------------	--------------------	---------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/799,302
		Filing Date	03/12/2004
		First Named Inventor	JEFFREY S. KIEL
		Group Art Unit	1615
		Examiner Name	
Sheet 3 of 3	Attorney Docket Number	455-030	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JS	1	CYPRESS PHARMACEUTICAL, INC., "R-Tannic-S A/D," RX Only, Cypress Pharmaceutical, Inc., (Madison, MS), p. 1, 2 (March 1, 2001).	
JS	2	DSC LABORATORIES, "Phenylephrine Tannate/Pyrimamine Tannate Suspension," RX Only, DSC Laboratories (Muskegon, MI), p. 1, 2 (Aug. 1, 2001).	
JS	3	RONALD GOLDBERG, M.D. and FRANKLIN SHUMAN, M.D., "Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders," Clinical Report, Clinical Medicine (Washington), Vol. 72 (No. 9), pp. 1475-1479 (Sept. 1, 1965).	
JS	4	JOHN WEILER, M.D. ET AL., "Randomized, double-blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan in the treatment of allergic rhinitis using an acute model," Annals of Allergy, ACAI (Iowa City, IA), Vol. 64 (No. 1), p. 63-67 (Jan. 1, 1990).	

Examiner Signature	/Jagadishwar Samal	Date/ (10/26/2006)	Considered
--------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.